Education and Training
Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: VPD-737
- drug: VPD-737
- other: Placebo
Eligibility
Inclusion Criteria:
- Clinical diagnosis of Epidermolysis Bullosa (EB) and pruritus
Exclusion Criteria:
- Chronic liver or renal disease
Ages Eligible for Study
13 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Claudia Teng
725-7152
Not Recruiting